Fractional laser and laser assisted corticosteroid delivery for hypertrophic scars in thermal burns

The unprecedented survival of individuals who sustain acute burns and other trauma has increased the necessity for effective modalities in the treatment and rehabilitation of patients. Hypertrophic scars and contractures are common following thermal burns injury. Cutaneous scars can be complex and thus the approach to therapy is often multimodal with only moderate success. Intralesional corticosteroids have long been a main treatment of hypertrophic and restrictive scars. Recent advance in laser technology and applications now provide additional options for improvements in function, symptoms, and cosmesis. The ablative zones created by fractional ablative lasers may also be used in the immediate post-operative period to enhance delivery of drugs and other substances. This case report shows the successful use of fractional laser assisted corticosteroid to treat burn scars. It is need more extensive clinical trial to prove this method can be a therapeutic option for the extensive cutaneous scarring in burn patients

The efficacy and safety of fractional erbium yag laser combined with topical amniotic membrane stem cell (AMSC) metabolite product for facial rejuvenation: A controlled, split-face study

Skin aging is a complex biological process, and it growing fast in number. Fractionated laser has been considered as the gold standard for skin rejuvenation. Stem cell-based therapy also becoming a promising new approach for treating this condition. To investigate the effect of fractional erbium laser and topical amniotic membrane stem cell (AMSC)-metabolite product (MP) on skin aging. A total of 9 female participants, were included in controlled split-face study. The participant’s face was randomly allocated to AMSC-MP or saline, immediately after fractional laser procedure. All participants received 3 sessions of treatment with 4-weeks intervals. An evaluation was done using pre- and post- treatment photographs and skin analyzer, Janus. Laser-assisted transdermal delivery drug using topical AMSC-MP give a better improvement on skin pore and spot UV compared with the control group. The wrinkle and skin tone showed different results maybe because of multifactorial factors influence. No serious adverse events were found. This study suggest that fractional erbium YAG laser treatment combined with topical AMSC–MP is effective and safe for facial rejuvenation in Asian patients

The efficacy and safety of fractional erbium yag laser combined with topical amniotic membrane stem cell (AMSC) metabolite product for facial rejuvenation: A controlled, split-face study

Abstract READ ONLINE Skin aging is a complex biological process, and it growing fast in number. Fractionated laser has been considered as the gold standard for skin rejuvenation. Stem cell-based therapy also becoming a promising new approach for treating this condition. To investigate the effect of fractional erbium laser and topical amniotic membrane stem cell (AMSC)-metabolite product (MP) on skin aging. A total of 9 female participants, were included in controlled split-face study. The participant’s face was randomly allocated to AMSC-MP or saline, immediately after fractional laser procedure. All participants received 3 sessions of treatment with 4-weeks intervals. An evaluation was done using pre- and post- treatment photographs and skin analyzer, Janus. Laser-assisted transdermal delivery drug using topical AMSC-MP give a better improvement on skin pore and spot UV compared with the control group. The wrinkle and skin tone showed different results maybe because of multifactorial factors influence. No serious adverse events were found. This study suggest that fractional erbium YAG laser treatment combined with topical AMSC–MP is effective and safe for facial rejuvenation in Asian patients

Potential for serodiagnosis of indonesian leprosy patients by detecting antibodies against LID-1

Leprosy is caused by Mycobacterium leprae infection and remains a major public health problem in many areas of the world. The Leprosy IDRI Diagnostic (LID)-1 antigen has demonstrated potential to improve the diagnostic capacity of local health centers and aid the development of strategies for the eventual control and elimination of leprosy from endemic areas. The diagnostic capacity of LID-1 has not yet, however, been studied in Indonesia. Objective: To determine the proportion of Indonesian leprosy patients that have circulating antibodies against LID-1. Sera from thirtyfive leprosy patients from Surabaya, Indonesia were evaluated using an Enzyme Linked Immunosorbent Assay (ELISA) detecting IgG antibodies against the LID-1 antigen. Anti-LID-1 antibody levels correlated with both the clinical form of leprosy and the bacterial index (BI). LID-1-specific IgG responses were higher in multibacillary (MB) than in paucibacillary (PB) leprosy patients. Our data indicate that the detection and measurement of serum IgG against LID-1 could be an effective tool for use in control programs in various states and municipalities in Indonesia

Lactobacillus plantarum IS-10506 supplementation reduced SCORAD in children with atopic dermatitis

Lactobacillus plantarum IS-10506 is a novel probiotic isolated from dadih, an Indonesian traditional fermented buffalo milk. It’s in vitro and in vivo probiotic properties have been assessed. Probiotic function has been shown in vivo by the suppression of allergic reactions in BALB/c mice through the action of T-regulatory cells cytokines by balancing Th1 and Th2 immune response. Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease characterised by the imbalance of Th1 and Th2. The aim of the study was to assess the probiotic function of L. plantarum IS-10506 in children with mild and moderate AD. A randomised double-blind placebo-controlled trial comparing microencapsulated L. plantarum IS-10506 (1010 cfu/day) and placebo (skim milk-Avicel) twice daily for 12 weeks was conducted in an outpatient clinic on children with mild and moderate AD. The trial included 22 AD children divided into intervention and control groups of n=12 and n=10 patients, respectively. Scoring Atopic Dermatitis Index (SCORAD) and serum immunoglobulin E (IgE), interleukin (IL)-4, interferon gamma (IFN-γ), forkhead box P3 (Foxp3+)/IL-10, and IL-17 levels were assessed. Demographic and baseline characteristics were not significantly different between the two groups. SCORAD and levels of IL-4, IFN-γ, and IL-17 were significantly lower in the probiotic group than those in the placebo group, while the IgE levels were not significantly changed. The ratio of Foxp3+ to IL-10 was significantly higher in the probiotic group than that in placebo group. Supplementation with the probiotic L. plantarum IS-10506 offered a potential treatment for children with AD. Further long-term studies with a larger sample size are required to confirm the therapeutic efficacy of L. plantarum IS-10506 in AD

An enhanced regimen as post-exposure chemoprophylaxis for leprosy:PEP+

The ongoing transmission of Mycobacterium (M.) leprae reflected in a very slow decline in leprosy incidence, forces us to be innovative and conduct cutting-edge research. Single dose rifampicin (SDR) as post-exposure prophylaxis (PEP) for contacts of leprosy patients, reduces their risk to develop leprosy by 60%. This is a promising new preventive measure that can be integrated into routine leprosy control programmes, as is being demonstrated in the Leprosy Post-Exposure Programme that is currently ongoing in eight countries.The limited (60%) effectiveness of SDR is likely due to the fact that some contacts have a preclinical infection beyond the early stages for which SDR is not sufficient to prevent the development of clinical signs and symptoms of leprosy. An enhanced regimen, more potent against a higher load of leprosy bacteria, would increase the effectiveness of this preventive measure significantly.The Netherlands Leprosy Relief (NLR) is developing a multi-country study aiming to show that breaking the chain of transmission of M. leprae is possible, evidenced by a dramatic reduction in incidence. In this study the assessment of the effectiveness of an enhanced prophylactic regimen for leprosy is an important component. To define the so called PEP++ regimen for this intervention study, NLR convened an Expert Meeting that was attended by clinical leprologists, public health experts, pharmacologists, dermatologists and microbiologists.The Expert Meeting advised on combinations of available drugs, with known efficacy against leprosy, as well as on the duration of the intake, aiming at a risk reduction of 80-90%. To come to a conclusion the Expert Meeting considered the bactericidal, sterilising and bacteriostatic activity of the potential drugs. The criteria used to determine an optimal enhanced regimen were: effectiveness, safety, acceptability, availability, affordability, feasibility and not inducing drug resistance.The Expert Meeting concluded that the enhanced regimen for the PEP++ study should comprise three standard doses of rifampicin 600 mg (weight adjusted when given to children) plus moxifloxacin 400 mg given at four-weekly intervals. For children and for adults with contraindications for moxifloxacin, moxifloxacin should be replaced by clarithromycin 300 mg (weight adjusted)

Correlation between disease severity and quality of life index in psoriasis patients treated with Lactobacillus plantarum IS-10506

Psoriasis is a chronic and relapsing inflammatory skin disease that affects both genders at all ages. The purpose of this study is to identify the correlation between psoriasis area severity index (PASI) and Dermatology Life Quality Index (DLQI) for patients with plaque psoriasis before and after treatment with Lactobacillus plantarum IS-10506. This was a before after cohort study. Adults with mild to moderate psoriasis were recruited into the study. All participants received the original Indonesian probiotic strain Lactobacillus plantarum IS-10506 at a dose of 2x1010 colony forming units (CFU) per day for six weeks. A total of 22 patients, with a mean age of 43 years, participated in the study. Participants had psoriasis for an average of 14 years. There was a correlation between PASI score and several quality-of-life questionnaire elements in certain condition, such as professional jobs, unemployment, obesity, and joint symptoms. The correlation between particular conditions reveals that occupations, obesity, and joint symptoms have a greater impact on psoriasis patients

Mycobacterium leprae BACILLEMIA IN BOTH TWINS, BUT ONLY MANIFEST AS LEPROSY IN ONE SIBLING

Leprosy in twins is rarely reported. A 19 years-old male student, from Lamongan district, was diagnosed as Multibacillary (MB) leprosy in the Skin and STD Clinic of Dr. Soetomo General Hospital Surabaya. Multiple anesthetic skin lesions were found, but the bacteriologic examination was negative for Acid Fast Bacilli (AFB). Histopathology examination support the diagnosis of BL type of leprosy. His twin brother that has been lived together since born until present seems healthy without any complaints of skin lesions and have no signs of leprosy. When a serologic examination for leprosy was performed, a high anti PGL-1 antibody level was found in patient (IgM anti PGL-1 2937 and IgG anti PGL-1 3080 unit/ml) while his healthy twin brother showed only low level (IgM 745 and IgG 0 unit/ml). Interestingly when a PCR study was performed to detect M.leprae in the blood, both of them showed positive results. Using the TTC method, a genomic study of for M.leprae, it is revealed that both samples were identic ( 27x TTC repeats). According to patient’s history, he had a traffic accident and got a wound in the knee seven years ago, while the skin lesions seems started from this area around three years ago before it spread to other parts of the body. The patient was treated with Multi-drug therapy (MDT) while his sibling got a prophylactic treatment for leprosy. After 6 months of treatment, the leprosy skin lesions were diminished and the serologic anti PGL 1 has been decreased. His healthy brother also showed a decrease in anti PGL 1 level and no skin signs of leprosy

The role of probiotics in the treatment of adult atopic dermatitis: a meta-analysis of randomized controlled trials

Umborowati MA, Damayanti D, Anggraeni S, et al. The role of probiotics in the treatment of adult atopic dermatitis: a meta-analysis of randomized controlled trials. Journal of Health Population and Nutrition. 2022;41(1): 37.Background Atopic dermatitis (AD) is chronic inflammatory skin disease that is relapsing and a serious condition that disrupts the quality of life of affected individuals. Probiotics are an immunomodulator that can enhance the immune control of atopic dermatitis. Methods All randomized controlled trials of probiotics for the treatment of adult AD published before December 2020 were included in this study from the PubMed databases and manual searching. Results Six randomized controlled trials (n = 241) were selected for this meta-analysis study. Probiotics were effective in treating adult patients with AD, indicated by the decrease in Scoring Atopic Dermatitis/SCORAD (Mean Difference (MD) - 7.90, 95% CI - 7.25 to - 6.92; p 0.05). Limitations The study found no available data for side effects of probiotics. Strength This meta-analysis analyzed a total of 241 AD patients of Asian and European origin. Conclusion The use of probiotics decreased SCORAD significantly in adult patients with AD. Probiotics can improve the quality of life of patients with AD. Capsule summary The use of probiotics in atopic dermatitis has been widely studied, with controversial results. This meta-analysis suggests that the use of probiotics can improve SCORAD and the quality of life of patients with atopic dermatitis

Data for "The Role of Probiotic on Clinical Improvement, Inflammatory Biomarkers, and Patient Quality of Life in Psoriasis Treatment : A Meta-Analysis of Randomized Controlled Clinical Trials with subgroup analysis"

This repository contains data for "The Role of Probiotic on Clinical Improvement, Inflammatory Biomarkers, and Patient Quality of Life in Psoriasis Treatment : A Meta-Analysis of Randomized Controlled Clinical Trials with subgroup analysis", including dataset and figures related to our study.</p